Press Enter to search · ESC to close

Macro

China NMPA Approves Eli Lilly’s Oral Weight-Loss Drug Orforglipron Calcium Tablets

China’s National Medical Products Administration has approved Eli Lilly’s Class 1 innovative drug orforglipron calcium tablets, marketed as Muyouda, for long-term weight management in adults. The drug is indicated alongside diet and exercise for adults with a baseline BMI of 30 kg/m2 or higher (obesity) or 27 kg/m2 or higher. The approval was granted to Eli Lilly Nederland B.V.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback